Market Research Logo

Global Vaccine Adjuvants Market Research Report, Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

Global Vaccine Adjuvants Market Research Report, Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

Adjuvants are the immunological agents deployed in vaccines for enhancing body’s immune response to the vaccine and its ability to induce protection against infection. The global vaccine adjuvants market is growing at a CAGR of 10.25% during forecast period 2016-2023. Increasing use of adjuvants in vaccine, high prevalence of infectious diseases and zoonotic diseases, increasing government focus on immunization programs, increasing geriatric population and increasing R&D in vaccine adjuvants are driving the growth of the market. According to Centre for Disease Control and Prevention, zoonotic diseases prevalence is found to be common in U.S. and around 10,000 American population every year get infected from germs that are communicable through animals. Further, it is stated that every 6 out of 10 people are infected from known infectious disease spread by animals. Moreover, occurrence of these diseases are found in children’s above age 5 and in adults of 65 age and above along with people having weak immune system. At this scenario of increasing communicable and zoonotic diseases, demand for proper vaccines increases which in return increases the demand for deploying adjuvants for enhancing immune response of patient to the vaccine.

Increasing focus on immunization programs by governments has accelerated growth of market, For instance, U.S. National Adult Immunization Program targeting specifically adults for vaccination with a goal of strengthening immunization infrastructure for adults, to develop better access to vaccines for adults, and develop new technologies related to vaccination and adult vaccine innovation. Further, India’s Universal Immunization Program (U.I.P) is one of the world’s largest programs in terms of quantities of vaccines used in program, in terms of area covered by program, in number of benefited peoples and programs organized. Further, China National Immunization Program is a government program with a goal to eliminate and control vaccine preventable diseases. The major companies in the market are, Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), and others.

Global market for vaccine adjuvants is expected to dominate by North America region during the forecast period due to high geriatric population and increased investment in healthcare sector. However, Asia-Pacific is expected to account for the fastest growth for forecast period due to the growing healthcare awareness and initiatives by government.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. GLOBAL VACCINE ADJUVANTS MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360 DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGION
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. INCREASING USE OF ADJUVANTS IN VACCINE
3.1.2. HIGH PREVALENCE OF INFECTIOUS AND ZOONOTIC DISEASES
3.1.3. INCREASE IN LIVESTOCK AND INSTANCES OF DISEASES
3.1.4. INCREASING GOVERNMENT FOCUS ON IMMUNIZATION PROGRAMS
3.1.5. INCREASING GERIATRIC POPULATION
3.2. MARKET RESTRAINTS
3.2.1. HIGH COST OF ADJUVANT RESEARCH
3.2.2. STRINGENT REGULATORY ENVIRONMENT AND TIME-CONSUMING APPROVALS
3.3. MARKET OPPORTUNITIES
3.3.1. INTRODUCTION OF COMBINATION ADJUVANTS
3.4. MARKET CHALLENGES
3.4.1. IDENTIFICATION OF ADJUVANTS
4. MARKET SEGMENTATION
4.1. GLOBAL VACCINE ADJUVANTS MARKET BY PRODUCT TYPE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. GLOBAL PARTICULATE ADJUVANTS MARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. KEY PLAYERS & KEY PRODUCTS
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL ADJUVANT EMULSIONS MARKET
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. KEY PLAYERS & KEY PRODUCTS
4.1.5.2.4. KEY CONCLUSIONS
4.1.5.3. GLOBAL PATHOGEN COMPONENTS MARKET
4.1.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.3.3. KEY PLAYERS & KEY PRODUCTS
4.1.5.3.4. KEY CONCLUSIONS
4.1.5.4. GLOBAL COMBINATION ADJUVANTS MARKET
4.1.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.4.3. KEY PLAYERS & KEY PRODUCTS
4.1.5.4.4. KEY CONCLUSIONS
4.1.5.5. GLOBAL OTHERS MARKET
4.1.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.5.3. KEY PLAYERS & KEY PRODUCTS
4.1.5.5.4. KEY CONCLUSIONS
4.2. GLOBAL VACCINE ADJUVANTS MARKET BY ROUTE OF ADMINISTRATION
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL INTRAMUSCULAR ROUTE MARKET
4.2.5.1.1. APPLICATION
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.4. KEY PLAYERS & KEY PRODUCTS
4.2.5.1.5. KEY CONCLUSIONS
4.2.5.2. GLOBAL SUBCUTANEOUS ROUTE MARKET
4.2.5.2.1. APPLICATION
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.4. KEY PLAYERS & KEY PRODUCTS
4.2.5.3. GLOBAL INTRANASAL ROUTE MARKET
4.2.5.3.1. APPLICATION
4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.4. KEY PLAYERS & KEY PRODUCTS
4.2.5.4. GLOBAL ORAL ROUTE MARKET
4.2.5.4.1. APPLICATION
4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.4. KEY PLAYERS & KEY PRODUCTS
4.2.5.5. GLOBAL INTRADERMAL ROUTE MARKET
4.2.5.5.1. APPLICATION
4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.4. KEY PLAYERS & KEY PRODUCTS
4.2.5.6. GLOBAL OTHERS MARKET
4.2.5.6.1. APPLICATION
4.2.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.6.4. KEY PLAYERS & KEY PRODUCTS
4.3. GLOBAL VACCINE ADJUVANTS MARKET BY DISEASE TYPE
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. GLOBAL INFECTIOUS DISEASES MARKET
4.3.5.1.1. APPLICATION
4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.4. KEY PLAYERS & KEY PRODUCTS
4.3.5.1.5. KEY CONCLUSIONS
4.3.5.2. GLOBAL CANCER MARKET
4.3.5.2.1. APPLICATION
4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.4. KEY PLAYERS & KEY PRODUCTS
4.3.5.2.5. KEY CONCLUSIONS
4.3.5.3. GLOBAL OTHERS MARKET
4.3.5.3.1. APPLICATION
4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.3.4. KEY PLAYERS & KEY PRODUCTS
4.3.5.3.5. KEY CONCLUSIONS
4.4. GLOBAL VACCINE ADJUVANTS MARKET BY APPLICATION CATEGORY
4.4.1. MARKET DEFINITION AND SCOPE
4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.4.4. OPPORTUNITY MATRIX
4.4.5. MARKET SEGMENTATION
4.4.5.1. GLOBAL HUMAN VACCINE ADJUVANTS MARKET
4.4.5.1.1. APPLICATION
4.4.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.1.4. KEY PLAYERS & KEY PRODUCTS
4.4.5.1.5. KEY CONCLUSIONS
4.4.5.2. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET
4.4.5.2.1. APPLICATION
4.4.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.2.4. KEY PLAYERS & KEY PRODUCTS
4.4.5.2.5. KEY CONCLUSIONS
4.5. GLOBAL VACCINE ADJUVANTS MARKET BY APPLICATION
4.5.1. MARKET DEFINITION AND SCOPE
4.5.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.5.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.5.4. OPPORTUNITY MATRIX
4.5.4.1.1. MARKET SEGMENTATION
4.5.4.2. GLOBAL RESEARCH APPLICATION MARKET
4.5.4.2.1. APPLICATION
4.5.4.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.5.4.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.5.4.2.4. KEY PLAYERS & KEY PRODUCTS
4.5.4.2.5. KEY CONCLUSIONS
4.5.4.3. GLOBAL COMMERCIAL APPLICATION MARKET
4.5.4.3.1. APPLICATION
4.5.4.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.5.4.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.5.4.3.4. KEY PLAYERS & KEY PRODUCTS
4.5.4.3.5. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGER & ACQUISITION
5.1.2. LIST OF JOINT VENTURE
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIP
5.2. TOP 10 COMPANY ANALYSIS
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL VACCINE ADJUVANTS MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. RUSSIA
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. ADJUVATIS (FRANCE)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. STRATEGIC INITIATIVES
7.1.4. SCOT ANALYSIS
7.1.5. STRATEGIC ANALYSIS
7.2. AGENUS, INC. (U.S.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. STRATEGIC INITIATIVES
7.2.4. SCOT ANALYSIS
7.2.5. STRATEGIC ANALYSIS
7.3. AGRILABS (U.S.)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. STRATEGIC INITIATIVES
7.3.4. SCOT ANALYSIS
7.3.5. STRATEGIC ANALYSIS
7.4. AKSHAYA BIO (CANADA)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. STRATEGIC INITIATIVES
7.4.4. SCOT ANALYSIS
7.4.5. STRATEGIC ANALYSIS
7.5. AVANTI POLAR LIPIDS, INC. (ALABAMA)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. STRATEGIC INITIATIVES
7.5.4. SCOT ANALYSIS
7.5.5. STRATEGIC ANALYSIS
7.6. BRENNTAG BIOSECTOR A/S (GERMANY)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. STRATEGIC INITIATIVES
7.6.4. SCOT ANALYSIS
7.6.5. STRATEGIC ANALYSIS
7.7. CSL LIMITED (AUSTRALIA)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. STRATEGIC INITIATIVES
7.7.4. SCOT ANALYSIS
7.7.5. STRATEGIC ANALYSIS
7.8. HUVEPHARMA (BULGARIA)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. STRATEGIC INITIATIVES
7.8.4. SCOT ANALYSIS
7.8.5. STRATEGIC ANALYSIS
7.9. INVIVOGEN (U.S.)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. STRATEGIC INITIATIVES
7.9.4. SCOT ANALYSIS
7.9.5. STRATEGIC ANALYSIS
7.10. MVP LABORATORIES, INC. (OMAHA)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. STRATEGIC INITIATIVES
7.10.4. SCOT ANALYSIS
7.10.5. STRATEGIC ANALYSIS
7.11. NOVAVAX, INC. (U.S.)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. STRATEGIC INITIATIVES
7.11.4. SCOT ANALYSIS
7.11.5. STRATEGIC ANALYSIS
7.12. OZ BIOSCIENCES (U.S.)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. STRATEGIC INITIATIVES
7.12.4. SCOT ANALYSIS
7.12.5. STRATEGIC ANALYSIS
7.13. SEPPIC (FRANCE)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. STRATEGIC INITIATIVES
7.13.4. SCOT ANALYSIS
7.13.5. STRATEGIC ANALYSIS
7.14. SIGMA ALDRICH (U.S.)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. STRATEGIC INITIATIVES
7.14.4. SCOT ANALYSIS
7.14.5. STRATEGIC ANALYSIS
7.14.6. SPI PHARMA, INC. (U.S.)OVERVIEW
7.14.7. PRODUCT PORTFOLIO
7.14.8. STRATEGIC INITIATIVES
7.14.9. SCOT ANALYSIS
7.14.10. STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL VACCINE ADJUVANTS MARKET BY PRODUCT TYPE 2014-2023 ($ MILLION)
GLOBAL PARTICULATE ADJUVANTS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL ADJUVANT EMULSIONS GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL PATHOGEN COMPONENTS BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL COMBINATION ADJUVANTS BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL OTHERS BY GEOGRAPHY 2014-2023 ($ MILLION)
VACCINE ADJUVANTS MARKET BY ROUTE OF ADMINISTRATION 2014-2023 ($ MILLION)
GLOBAL INTRAMUSCULAR ROUTE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL SUBCUTANEOUS ROUTE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL INTRANASAL ROUTE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL ORAL ROUTE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL INTRADERMAL ROUTE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL VACCINE ADJUVANTS MARKET BY DISEASE TYPE 2014-2023 ($ MILLION)
GLOBAL INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL CANCER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL VACCINE ADJUVANTS MARKET BY APPLICATION 2014-2023 ($ MILLION)
GLOBAL RESEARCH APPLICATIONS BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL COMMERCIAL APPLICATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY 2014-2023 ($ MILLION)
GLOBAL HUMAN VACCINE ADJUVANTS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL VETERINARY VACCINE ADJUVANTS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
NORTH AMERICA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
EUROPE VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
ASIA PACIFIC VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
REST OF THE WORLD VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
LIST OF FIGURES
GLOBAL PARTICULATE ADJUVANTS MARKET 2014-2023 ($ MILLION)
GLOBAL ADJUVANT EMULSIONS MARKET 2014-2023 ($ MILLION)
GLOBAL PATHOGEN COMPONENTS MARKET 2014-2023 ($ MILLION)
GLOBAL COMBINATION ADJUVANTS MARKET 2014-2023 ($ MILLION)
GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
GLOBAL INTRAMUSCULAR ROUTE MARKET 2014-2023 ($ MILLION)
GLOBAL SUBCUTANEOUS ROUTE MARKET 2014-2023 ($ MILLION)
GLOBAL INTRANASAL ROUTE MARKET 2014-2023 ($ MILLION)
GLOBAL ORAL ROUTE MARKET 2014-2023 ($ MILLION)
GLOBAL INTRADERMAL ROUTE MARKET 2014-2023 ($ MILLION)
GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
GLOBAL INFECTIOUS DISEASES MARKET 2014-2023 ($ MILLION)
GLOBAL CANCER MARKET 2014-2023 ($ MILLION)
GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
GLOBAL RESEARCH APPLICATIONS MARKET 2014-2023 ($ MILLION)
GLOBAL COMMERCIAL APPLICATIONS MARKET 2014-2023 ($ MILLION)
GLOBAL HUMAN VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
GLOBAL VETERINARY VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
UNITED STATES (U.S.) VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
CANADA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
UNITED KINGDOM (UK) VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
FRANCE VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
GERMANY VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
RUSSIA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
ROE VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
INDIA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
CHINA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
JAPAN VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
AUSTRALIA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
ROAPAC VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
LATIN AMERICA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)
MENA VACCINE ADJUVANTS MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report